Chinese cosmetics and biomedical company Bloomage BioTech, is on the lookout for acquisitions, chief executive Xuekun Jin told FinanceAsia on Thursday.
The Hong Kong-listed corporation has acquired two European businesses already, paying 59 million $63.7 million for French cosmetic device maker Vivacy in 2015 and 25.15 million for Revitacare, another French manufacturer, in January. But Jin is eager to gobble up more overseas rivals.
“We have some targets, and we’re working together with a partner,” he said, adding that the company is considering acquisitions in both Europe and the United States.
Bloomage will be helped in its search by its relationship with...